Wednesday, February 8, 2012

Protox gets credibility boost from Warburg Pincus

November 9, 2010 by leonardzehr · Leave a Comment

An equity injection of up to $35 million from private equity giant Warburg Pincus represents a huge vote of confidence in Protox Therapeutics (TSX:PRX) and its lead PRX302 drug for enlarged prostate or benign prostatic hyperplasia (BPH), with the drug potentially able to target two other diseases: prostate cancer and prostatitis. “We went through an [...]

Filed under Tuesday Features · Tagged with Abbott, Astellas Pharma, benign prostatic hyperplasia, Boehringer Ingelheim, BPH, David Martin, Decision Resources, Dr. Fahar Merchant, Dr. Lars Ekman, Dundee Capital Markets, Endo Pharma, enlarged prostate, FDA, GlaxoSmithKline, IND, International Prostate Symptom Score, IPSS, Kissei Pharmaceutical, Merck, Pfizer, Protox Therapeutics, PRX, PRX302, Sanofi-Aventis, TSX, Urief, urology, Warburg Pincus, Watson Pharma

Protox lands licensing deal in Japan

April 30, 2010 by stephenkilmer · Leave a Comment

Protox Therapeutics (TSX:PRX) has signed a potential $75 million (U.S.) licence agreement with Kissei Pharmaceutical to develop and commercialize Protox’s PRX302 drug in Japan for the treatment of enlarged prostate, prostate cancer and other diseases of the prostate. Under the accord, Protox will receive an upfront payment of $3 million and is eligible to receive [...]

Filed under Briefs · Tagged with Doug Loe, Kissei Pharmaceutical, Protox, PRX, PRX302, Versant